Events Past Events Immunovant Reports Financial Results for the Quarter Ended June 30, 2021 Aug 9, 2021 at 8:00 AM EDT Click here for webcast Immunovant Corporate Update Jun 1, 2021 at 8:00 AM EDT Click here for webcast Immunovant Provides Corporate Update Feb 2, 2021 at 8:00 AM EST Click here for webcast Immunovant Announces Positive Topline Results from ASCEND MG, A Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis Aug 25, 2020 at 8:30 AM EDT Click here for webcast Immunovant Discusses Initial Results From ASCEND GO 1, An Open-Label Phase 2a trial of IMVT-1401 In Thyroid Eye Disease, and Provides Corporate Update Mar 30, 2020 at 8:30 AM EDT Click here for webcast
Immunovant Reports Financial Results for the Quarter Ended June 30, 2021 Aug 9, 2021 at 8:00 AM EDT Click here for webcast
Immunovant Announces Positive Topline Results from ASCEND MG, A Multi-Center, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis Aug 25, 2020 at 8:30 AM EDT Click here for webcast
Immunovant Discusses Initial Results From ASCEND GO 1, An Open-Label Phase 2a trial of IMVT-1401 In Thyroid Eye Disease, and Provides Corporate Update Mar 30, 2020 at 8:30 AM EDT Click here for webcast
